Skip to main content

Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More

COVID-19 Updates

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, virtual visits and more. Learn More


Texas Medical Center
The Woodlands

Pulmonary Medicine
Phone: 832-822-3300 (Main) | 936-267-7744 (The Woodlands)
Fax: 832-825-3308


Texas Children's Hospital - Main Campus
6701 Fannin Street
9th Floor
Houston, TX 77030

Texas Children's Hospital - The Woodlands
17580 I-45 South
6th Floor, Green Pod
The Woodlands, TX 77384

Peter W. Hiatt, MD

Chief of Pulmonary Medicine Service


School Education Degree Year
Indiana University School of Medicine Fellowship Pulmonary 1986
Indiana University School of Medicine Residency Pediatrics 1983
Indiana University School of Medicine Internship Pediatrics 1981
University of Iowa Hospitals and Clinics Medical School Doctor of Medicine 1980


Dr. Hiatt is the Chief of the Pulmonary section at Texas Children’s Hospital.  His clinical areas of interest include Cystic Fibrosis (CF) and General Pediatric Pulmonology.  He has devoted the last 25 years to CF focused on both clinical care and CF related research.  He continues to be involved with new drug therapy for CF.  He is the principal investigator for the Therapeutic Development Network at Baylor College of Medicine and remains involved in several Phase I, II and III clinical trials for the development of new medications to treat Cystic Fibrosis.


Organization Name Role
American Academy of Pediatrics Fellow
American Thoracic Society Member

Selected Publications

Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis.  Cameron LH, Peloquin CA, Hiatt P, Mann M, Starke JR, Faircloth J, McNeil JC, Patel A, Ruiz F.J Cyst Fibros. 2021 Aug 31:S1569-1993(21)01351-5. doi: 10.1016/j.jcf.2021.08.010. Online ahead of print.PMID: 34479810.

Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial.  Ratjen F, Davis SD, Stanojevic S, Kronmal RA, Hinckley Stukovsky KD, Jorgensen N, Rosenfeld M; SHIP Study Group.Lancet Respir Med. 2019 Sep;7(9):802-809. doi: 10.1016/S2213-2600(19)30187-0. Epub 2019 Jun 6.PMID: 31178421 Clinical Trial.

Rare loss of function variants in candidate genes and risk of colorectal cancer.  Rosenthal EA, Shirts BH, Amendola LM, Horike-Pyne M, Robertson PD, Hisama FM, Bennett RL, Dorschner MO, Nickerson DA, Stanaway IB, Nassir R, Vickers KT, Li C, Grady WM, Peters U, Jarvik GP; NHLBI GO Exome Sequencing Project.Hum Genet. 2018 Oct;137(10):795-806. doi: 10.1007/s00439-018-1938-4. Epub 2018 Sep 28.PMID: 30267214 Free PMC article. Clinical Trial.

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.  Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group.Lancet Respir Med. 2018 Jul;6(7):545-553. doi: 10.1016/S2213-2600(18)30202-9. Epub 2018 Jun 7.PMID: 29886024 Free PMC article. Clinical Trial.

Patient and Family Comments

* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.